Achieve Life Sciences Inc. has released a corporate presentation highlighting Cytisinicline as a potential new treatment for nicotine dependence, marking the first advancement in nearly 20 years. The company targets a substantial market of up to 50 million Americans who use tobacco, aiming to address the significant public health issue of nicotine dependence. The presentation outlines the anticipated FDA approval timeline, with a smoking cessation NDA filed and a launch expected in the second half of 2026. Additionally, the company is preparing for Phase 3 trials for an e-cigarette cessation indication, which holds an FDA Breakthrough Therapy designation and Priority Review. Achieve Life Sciences plans a focused launch strategy utilizing innovative, data-driven solutions to promote adoption and future growth. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。